Biography
Tasuku Honjo, a Japanese physician-scientist and immunologist, transformed cancer treatment with his pioneering work on the immune system. Born on January 27, 1942, in Kyoto, Japan, Honjo focused his career on unraveling the molecular basis of immune responses. His biggest breakthrough came with his discovery of programmed cell death protein 1 (PD-1), which changed the face of cancer immunotherapy and won him the 2018 Nobel Prize in Physiology or Medicine, alongside American immunologist James P. Allison.
Honjo's education took place at top-tier Japanese schools. He attended Yamaguchi Prefectural Ube High School and then went on to Kyoto University, where he honed his skills in immunology and molecular biology. This academic background laid the foundation for his influential research on the immune system and its potential for therapy.
During his esteemed career, Honjo made pivotal discoveries beyond PD-1, significantly advancing immunology. He identified cytokines IL-4 and IL-5, which are key to immune signaling and allergic reactions. He also discovered activation-induced cytidine deaminase (AID), an enzyme critical for antibody production processes like class switch recombination and somatic hypermutation. These findings have deepened our understanding of immune adaptation and threat response.
Honjo has received many esteemed awards and honors over his career. These include the Asahi Prize in 1981, the Imperial Prize of Japan Academy in 1996, recognition as a Person of Cultural Merit in 2000, the Robert Koch Prize in 2012, and the Order of Culture in 2013. He also won the Tang Prize in 2014, the William B. Coley Award in 2014, the Keio Medical Science Prize in 2016, and the Kyoto Prize in Basic Sciences in 2016, all leading up to his Nobel Prize.
The global scientific community has recognized Honjo's work through his membership in several leading academies. He became a foreign associate of the National Academy of Sciences in the U.S. in 2001, joined the German Academy of Natural Scientists Leopoldina in 2003, and was elected a member of the Japan Academy in 2005. These memberships highlight his worldwide impact on immunology and his contributions to advancing scientific understanding internationally.
Before Fame
Honjo's early life in Kyoto during the 1940s and 1950s was during Japan's post-World War II reconstruction, a time when the country was rebuilding its educational and scientific institutions. Growing up in this environment of renewal and modernization, he saw Japan become a global leader in scientific research and technology. His years at Yamaguchi Prefectural Ube High School coincided with Japan's rapid economic growth, which included major investments in higher education and research infrastructure.
Honjo's path to immunology developed during a time when molecular biology was advancing rapidly. The 1960s and 1970s, when he was building his career, were the golden age of molecular biology discoveries, including the understanding of DNA structure, protein synthesis, and cellular mechanisms. This scientific boom provided the technology and knowledge necessary for his later breakthroughs in immune system research, especially his work on PD-1 and identifying cytokines.
Key Achievements
- Identification of programmed cell death protein 1 (PD-1), leading to breakthrough cancer immunotherapy treatments
- Molecular identification of cytokines IL-4 and IL-5, advancing understanding of immune signaling pathways
- Discovery of activation-induced cytidine deaminase (AID) essential for antibody class switching and somatic hypermutation
- Recipient of 2018 Nobel Prize in Physiology or Medicine shared with James P. Allison
- Election to multiple prestigious international scientific academies including the National Academy of Sciences
Did You Know?
- 01.His discovery of PD-1 initially faced skepticism from the scientific community, as its function as an immune checkpoint inhibitor was not immediately understood
- 02.Honjo's identification of IL-4 and IL-5 cytokines contributed significantly to understanding allergic reactions and asthma pathophysiology
- 03.He shares his 2018 Nobel Prize with James P. Allison, with whom he also shared the 2014 Tang Prize for the same research
- 04.The activation-induced cytidine deaminase (AID) enzyme he discovered is crucial for antibody diversity, allowing the immune system to create billions of different antibodies
- 05.His PD-1 research has led to the development of checkpoint inhibitor drugs that have extended survival rates for patients with previously untreatable cancers
Awards & Honors
| Award | Year | Details |
|---|---|---|
| Nobel Prize in Physiology or Medicine | 2018 | for their discovery of cancer therapy by inhibition of negative immune regulation |
| Tang Prize | 2014 | — |
| Asahi Prize | 1981 | — |
| Imperial Prize of Japan Academy | 1996 | — |
| Person of Cultural Merit | 2000 | — |
| Robert Koch Prize | 2012 | — |
| Order of Culture | 2013 | — |
| William B. Coley Award | 2014 | — |
| Keio Medical Science Prize | 2016 | — |
| Kyoto Prize in Basic Sciences | 2016 | — |
| Clarivate Citation Laureates | 2016 | — |
| Warren Alpert Foundation Prize | 2017 | — |
| honorary doctor of the Aix-Marseille University | 2021 | — |